Details of the Drug

General Information of Drug (ID: DMOJ0V6)

Drug Name

Metoprolol

Synonyms

Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2], [3]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

267.36

Topological Polar Surface Area (xlogp)

1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 95% [5]
Clearance: The clearance of drug is 0.8 L/min [6]
Elimination: Metoprolol is mainly excreted via the kidneys, and less than 5% is recovered unchanged [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 7 hours [7]
Metabolism: The drug is metabolized via the hepatic [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.94657 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.88% [9]
Vd: The volume of distribution (Vd) of drug is 4.2 L/kg [10]
Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [4]

Chemical Identifiers

Formula: C15H25NO3
IUPAC Name: 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
InChI: InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
InChIKey: IUBSYMUCCVWXPE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4171
ChEBI ID: CHEBI:6904
CAS Number: 51384-51-1
DrugBank ID: DB00264
TTD ID: D0I2MK
VARIDT ID: DR00436
INTEDE ID: DR1071
ACDINA ID: D00424

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[11], [12], [13]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[16]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Metoprolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Nisoldipine	DM7ISKJ	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Nisoldipine.	Hypertension [BA00-BA04]	[57]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Levamlodipine.	Hypertension [BA00-BA04]	[57]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Metoprolol and Doxazosin.	Hypertension [BA00-BA04]	[58]
Isradipine	DMA5XGH	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Isradipine.	Hypertension [BA00-BA04]	[57]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Metoprolol and Verapamil.	Hypertension [BA00-BA04]	[57]
Diltiazem	DMAI7ZV	Major	Increased risk of cardiac depression by the combination of Metoprolol and Diltiazem.	Hypertension [BA00-BA04]	[57]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Amlodipine.	Hypertension [BA00-BA04]	[57]
Indapamide	DMGN1PW	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Indapamide.	Hypertension [BA00-BA04]	[59]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of ventricular arrhythmias by the combination of Metoprolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[59]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Felodipine.	Hypertension [BA00-BA04]	[57]
Hydralazine	DMU8JGH	Minor	Decreased metabolism of Metoprolol caused by Hydralazine mediated interference with first-pass metabolism.	Hypertension [BA00-BA04]	[60]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hyperglycemia by the combination of Metoprolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[59]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[57]
-----------


⏷ Show the Full List of 13 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Metoprolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sucralfate	DMP9HBO	Minor	Decreased absorption of Metoprolol due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[61]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Metoprolol and Scopolamine.	Addictive disorder [6C50-6C5Z]	[62]
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Bepridil.	Angina pectoris [BA40]	[57]
Dronedarone	DMA8FS5	Moderate	Increased risk of bradycardia by the combination of Metoprolol and Dronedarone.	Angina pectoris [BA40]	[63]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Nifedipine.	Angina pectoris [BA40]	[57]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Metoprolol caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[64]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Metoprolol and Promazine.	Appearance/behaviour symptom [MB23]	[65]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Metoprolol caused by Zileuton.	Asthma [CA23]	[66]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Metoprolol caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[67]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Metoprolol and Cariprazine.	Bipolar disorder [6A60]	[65]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Metoprolol caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[68]
Atracurium	DM42HXN	Moderate	Additive cardiorespiratory depression effects by the combination of Metoprolol and Atracurium.	Corneal disease [9A76-9A78]	[69]
Mivacurium	DM473VD	Moderate	Additive cardiorespiratory depression effects by the combination of Metoprolol and Mivacurium.	Corneal disease [9A76-9A78]	[69]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Metoprolol and Pancuronium.	Corneal disease [9A76-9A78]	[69]
Tubocurarine	DMBZIVP	Moderate	Additive cardiorespiratory depression effects by the combination of Metoprolol and Tubocurarine.	Corneal disease [9A76-9A78]	[69]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Nimodipine.	Coronary vasospastic disease [BA85]	[57]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Metoprolol and Pasireotide.	Cushing syndrome [5A70]	[70]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Metoprolol caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Metoprolol caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Metoprolol caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Metoprolol caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[72]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Metoprolol and OPC-34712.	Depression [6A70-6A7Z]	[65]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Metoprolol when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[73]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Metoprolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[62]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Metoprolol when combined with Oxybutynine.	Discovery agent [N.A.]	[62]
Trihexyphenidyl	DMB19L8	Moderate	Additive CNS depression effects by the combination of Metoprolol and Trihexyphenidyl.	Dystonic disorder [8A02]	[62]
Diazepam	DM08E9O	Minor	Decreased metabolism of Metoprolol caused by Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[74]
Primidone	DM0WX6I	Moderate	Increased metabolism of Metoprolol caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[68]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Metoprolol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[75]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Metoprolol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[68]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Ethacrynic acid.	Essential hypertension [BA00]	[59]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of ventricular arrhythmias by the combination of Metoprolol and Bendroflumethiazide.	Essential hypertension [BA00]	[59]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Metoprolol and Phenoxybenzamine.	Essential hypertension [BA00]	[58]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Metoprolol and Nicardipine.	Essential hypertension [BA00]	[57]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Benzthiazide.	Essential hypertension [BA00]	[59]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Metoprolol and Phenylephrine.	Faecal incontinence [ME07]	[76]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Metoprolol caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[77]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Metoprolol and Tolterodine.	Functional bladder disorder [GC50]	[62]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Metoprolol caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[78]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Metoprolol caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[79]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Metoprolol when combined with Propantheline.	Gastric ulcer [DA60]	[62]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Metoprolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[80]
Spironolactone	DM2AQ5N	Moderate	Increased risk of hyperglycemia by the combination of Metoprolol and Spironolactone.	Heart failure [BD10-BD1Z]	[59]
Triamterene	DM2HU9I	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Triamterene.	Heart failure [BD10-BD1Z]	[59]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Metoprolol and Prazosin.	Heart failure [BD10-BD1Z]	[58]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyperglycemia by the combination of Metoprolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[59]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Furosemide.	Heart failure [BD10-BD1Z]	[59]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyperglycemia by the combination of Metoprolol and Bumetanide.	Heart failure [BD10-BD1Z]	[59]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Metoprolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[59]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Metoprolol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[81]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Metoprolol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[82]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Metoprolol caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[83]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Metoprolol caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[84]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Metoprolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[62]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Metoprolol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[68]
Pentobarbital	DMFNH7L	Moderate	Increased metabolism of Metoprolol caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[68]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Metoprolol and Propiomazine.	Insomnia [7A00-7A0Z]	[65]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Metoprolol and ITI-007.	Insomnia [7A00-7A0Z]	[65]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Metoprolol when combined with Clidinium.	Irritable bowel syndrome [DD91]	[62]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Metoprolol when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[62]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Metoprolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[62]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Metoprolol caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[85]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Metoprolol caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[73]
Chloroquine	DMSI5CB	Minor	Decreased metabolism of Metoprolol caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[86]
Hydroxychloroquine	DMSIVND	Minor	Decreased metabolism of Metoprolol caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[87]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Metoprolol caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[88]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Metoprolol caused by Ethinyl estradiol mediated interference with first-pass metabolism.	Menopausal disorder [GA30]	[89]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Metoprolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[70]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Metoprolol caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[90]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Metoprolol and Thalidomide.	Multiple myeloma [2A83]	[73]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Metoprolol and Siponimod.	Multiple sclerosis [8A40]	[73]
Fingolimod	DM5JVAN	Major	Increased risk of atrioventricular block by the combination of Metoprolol and Fingolimod.	Multiple sclerosis [8A40]	[91]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Metoprolol and Ozanimod.	Multiple sclerosis [8A40]	[92]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Metoprolol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[62]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Metoprolol caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[93]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Metoprolol caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[94]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Metoprolol and Prochlorperazine.	Nausea/vomiting [MD90]	[65]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Metoprolol and Promethazine.	Nausea/vomiting [MD90]	[65]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Metoprolol caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[95]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Metoprolol and Thiethylperazine.	Nausea/vomiting [MD90]	[65]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Metoprolol caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[96]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Metoprolol caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[97]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Chlorthalidone.	Oedema [MG29]	[59]
Metolazone	DMB39LO	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Metolazone.	Oedema [MG29]	[59]
Polythiazide	DMCH80F	Moderate	Increased risk of hypertriglyceridemia by the combination of Metoprolol and Polythiazide.	Oedema [MG29]	[59]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Metoprolol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[98]
Biperiden	DME78OA	Moderate	Altered absorption of Metoprolol due to GI dynamics variation caused by Biperiden.	Parkinsonism [8A00]	[62]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Metoprolol when combined with Procyclidine.	Parkinsonism [8A00]	[62]
Methylscopolamine	DM5VWOB	Moderate	Altered absorption of Metoprolol due to GI dynamics variation caused by Methylscopolamine.	Peptic ulcer [DA61]	[62]
Prednisone	DM2HG4X	Moderate	Antagonize the effect of Metoprolol when combined with Prednisone.	Postoperative inflammation [1A00-CA43]	[62]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Metoprolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[99]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Metoprolol and Terazosin.	Prostate hyperplasia [GA90]	[58]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Metoprolol and Alfuzosin.	Prostate hyperplasia [GA90]	[58]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Metoprolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[65]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Metoprolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[65]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Metoprolol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[65]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Metoprolol caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[100]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Metoprolol and Quetiapine.	Schizophrenia [6A20]	[65]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Metoprolol and Mesoridazine.	Schizophrenia [6A20]	[65]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Metoprolol and Thioridazine.	Schizophrenia [6A20]	[65]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Metoprolol and Aripiprazole.	Schizophrenia [6A20]	[65]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Metoprolol and Iloperidone.	Schizophrenia [6A20]	[65]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Metoprolol and Paliperidone.	Schizophrenia [6A20]	[65]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Metoprolol and Loxapine.	Schizophrenia [6A20]	[65]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Metoprolol and Haloperidol.	Schizophrenia [6A20]	[65]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Metoprolol and Perphenazine.	Schizophrenia [6A20]	[65]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Metoprolol and Molindone.	Schizophrenia [6A20]	[65]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Metoprolol and Chlorpromazine.	Schizophrenia [6A20]	[65]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Metoprolol and Thiothixene.	Schizophrenia [6A20]	[65]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Metoprolol and Trifluoperazine.	Schizophrenia [6A20]	[65]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Metoprolol and Risperidone.	Schizophrenia [6A20]	[65]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Metoprolol and Olanzapine.	Schizophrenia [6A20]	[65]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Metoprolol and Amisulpride.	Schizophrenia [6A20]	[62]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Metoprolol and Asenapine.	Schizophrenia [6A20]	[65]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Metoprolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[69]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Metoprolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[69]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Metoprolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[69]
Cisatracurium	DMUZPJ5	Moderate	Additive cardiorespiratory depression effects by the combination of Metoprolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[69]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Metoprolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[69]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Metoprolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[62]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Metoprolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[65]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Metoprolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[101]
Disopyramide	DM5SYZP	Major	Additive hypotensive effects by the combination of Metoprolol and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[102]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Metoprolol caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[103]
Amiodarone	DMUTEX3	Moderate	Increased risk of atrioventricular block by the combination of Metoprolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[104]
-----------


⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrochloric acid	E00015	313	Acidulant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Acetyltributyl citrate	E00127	6505	Plasticizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose anhydrous	E00394	107526	Binding agent; Diluent; Flavoring agent; Tonicity agent
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
Sodium sulhydrate	E00549	23665763	Antimicrobial preservative
--------------------


⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Metoprolol 37.5 mg tablet	37.5 mg	Oral Tablet	Oral
Metoprolol 25 mg tablet	25 mg	Oral Tablet	Oral
Metoprolol 100 mg tablet	100 mg	24 HR Extended Release Oral Tablet	Oral
Metoprolol 200 mg tablet	200 mg	24 HR Extended Release Oral Tablet	Oral
Metoprolol 200 mg tablet	200 mg	24 HR Extended Release Tablet	Oral
Metoprolol 25 mg tablet	25 mg	24 HR Extended Release Oral Tablet	Oral
Metoprolol 25 mg tablet	25 mg	24 HR Extended Release Tablet	Oral
Metoprolol 50 mg tablet	50 mg	24 HR Extended Release Oral Tablet	Oral
Metoprolol 50 mg tablet	50 mg	24 HR Extended Release Tablet	Oral
Metoprolol 50 mg tablet	50 mg	Oral Tablet	Oral
Metoprolol 75 mg tablet	75 mg	Oral Tablet	Oral
Metoprolol 100 mg tablet	100 mg	Oral Tablet	Oral
Metoprolol 100 mg tablet	100 mg	24 HR Extended Release Tablet	Oral
Metoprolol Tartrate eq 50mg base/100ml injectable	eq 50mg base/100ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 553).
2	Metoprolol: a review of its use in chronic heart failure. Drugs. 2000 Sep;60(3):647-78.
3	The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Mol Pharm. 2004 Sep-Oct;1(5):357-62.
4	BDDCS applied to over 900 drugs
5	Loxoprofen Sodium
6	Regardh CG, Jordo L, Ervik M, Lundborg P, Olsson R, Ronn O: Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981 Sep-Oct;6(5):375-88. doi: 10.2165/00003088-198106050-00004.
7	Metoprolol .
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
11	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
12	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
13	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
14	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
15	Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
16	The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
17	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
18	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
28	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
29	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
30	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
31	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
32	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
33	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
34	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
35	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
36	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
37	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
38	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
39	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
40	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
41	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
42	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
43	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
44	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
45	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
46	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
47	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
48	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
49	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
50	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
51	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
52	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
53	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
54	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
55	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
56	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
57	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
58	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
59	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
60	Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
61	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
62	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
63	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
64	Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
65	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
66	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
67	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
68	Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
69	Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
70	Canadian Pharmacists Association.
71	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
72	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
73	Cerner Multum, Inc. "Australian Product Information.".
74	Hawksworth G, Betts T, Crowe A, et al "Diazepam/beta-adrenoceptor antagonist interactions." Br J Clin Pharmacol 17 Suppl 1 (1984): s69-76. [PMID: 6146341]
75	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
76	Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
77	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
78	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
79	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
80	Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
81	Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
82	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
83	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
84	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
85	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
86	Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
87	Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M "Influence of hydroxychloroquine on the bioavailability of oral metoprolol." Br J Clin Pharmacol 49 (2000): 549-54. [PMID: 10848718]
88	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
89	Product Information. Betapace (sotalol). Berlex, Richmond, CA.
90	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
91	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
92	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
93	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
94	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
95	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
96	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
97	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
98	Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
99	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
100	Bengtsson C, Johnsson G, Regardh C-G "Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment." Clin Pharmacol Ther 17 (1975): 400-8. [PMID: 235398]
101	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
102	Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
103	Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
104	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]